基因预测的血代谢物调解了肠道微生物群和原发性免疫血栓缩 (ITP) 之间的因果关系
Yang Hong1, Cuilin Zhang1, Kai Shen1
1Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Frontiers in microbiology
|November 12, 2024
概括
肠道微生物群通过血代谢物影响免疫性血栓塞缩症 (ITP). 斯芬哥米林,葡萄糖与曼诺斯的比率和胆红素的比率是关键的中间体,为ITP提供了新的诊断和治疗目标.
科学领域:
- 微生物组研究的研究.
- 代谢学 代谢学 代谢学
- 免疫学 免疫学 免疫学
背景情况:
- 初级免疫血小板缺血 (ITP) 是一种免疫疾病,导致血小板数量低下和出血风险.
- 肠道微生物群的改变与ITP的发展有关,但涉及血代谢物的机制尚不清楚.
- 研究肠道微生物群-血代谢物-ITP轴对于了解疾病进展至关重要.
研究的目的:
- 使用孟德尔随机化 (MR) 选肠道微生物群和与ITP有因果关系的血代谢物.
- 为了确定调解肠道微生物群对ITP影响的血代谢物.
- 量化已识别的代谢物中介效应.
主要方法:
- 利用了肠道微生物群,血代谢物和ITP队列的总结GWAS数据.
- 采用双样本门德尔随机化 (MR) 方法,主要使用反方差加权 (IVW) 方法.
- 使用MR Egger和MR-PRESSO方法评估异质性和性.
主要成果:
- 确定了8种与ITP有因果关系的肠道微生物群.
- 在排除类代谢物后,发现了39种与ITP有因果关系的血代谢物.
- 斯芬戈米林,葡萄糖与曼诺斯的比率和胆红素的比率被确定为将特定的肠道细菌 (Intestinimonas,Senegalimassilia) 与ITP联系起来的中间体.
结论:
- 肠道微生物群通过血代谢物变化显著影响ITP的发展.
- 斯芬哥米林,葡萄糖与曼诺斯的比率,以及比利鲁 (Z,Z) 与乙醇醇糖的比率,代表了新的中间生物标志物.
- 这些发现为ITP临床诊断和治疗策略提供了潜在的新途径.
相关概念视频
Irritable Bowel Syndrome I: Introduction
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...


